Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfacon-2
- Development stage
- Phase 3
- Lead developer
- InterMune
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Peginterferon alfacon-2 is a synthetic, pegylated form of interferon alfa designed to enhance the pharmacokinetic properties of the native protein. It is a recombinant type I interferon produced in Escherichia coli and chemically modified with polyethylene glycol (PEG) to prolong its half-life and improve dosing convenience. Peginterferon alfacon-2 exerts its antiviral effects by binding to type I interferon receptors on cell surfaces, activating the JAK/STAT signaling pathway, which leads to increased expression of genes involved in antiviral defense and immune modulation. The drug was primarily developed for the treatment of chronic hepatitis C infection but has largely been replaced by newer direct acting antivirals due to superior efficacy and tolerability profiles.
- Brand names
- Infergen
- Other names
- pegylated interferon alfacon-2PEG IFN alfacon-2
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on peginterferon alfacon-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfacon-2.